Ascendis Pharma A (ASND) Net Equity Issued and Repurchased (2020 - 2026)
Ascendis Pharma A's Net Equity Issued and Repurchased was $21.46 million in the quarter ended Jun 30, 2026, up 52.0% from $14.11 million a year earlier but down 42.0% from the prior quarter.
Ascendis Pharma A (ASND) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, Ascendis Pharma A's Net Equity Issued and Repurchased was $129.46 million through Jun 30, 2026, up 237.2% year-over-year; for the year ended Dec 31, 2025, it came in at $98.38 million, up 197.9% from the prior year.
- Net Equity Issued and Repurchased has now increased for three consecutive years, with a five-year compound annual growth rate of 25.1% (years ended Dec 2020 to Dec 2025).
- In earlier years, Net Equity Issued and Repurchased was $33.03 million in the year ended Dec 31, 2024 (+196.8%), $11.13 million in the year ended Dec 31, 2023 (+104.9%), $5.43 million in the year ended Dec 31, 2022 (-58.8%) and $13.2 million in the year ended Dec 31, 2021 (-58.8%).
- Quarterly Net Equity Issued and Repurchased has moved between $226,496 (the quarter ended Jun 30, 2023) and $53.1 million (the quarter ended Sep 30, 2025) over five years.
- Compared with a year earlier, Net Equity Issued and Repurchased has increased for four straight quarters, with growth averaging 197.9% over the last seven quarters.
- The best year-over-year quarter for Net Equity Issued and Repurchased over five years was the quarter ended Sep 30, 2025 (growth of 718.7%); the worst was the quarter ended Jun 30, 2022 (a decline of 90.5%).
- Per Business Quant data, ASND's Net Equity Issued and Repurchased in the three quarters before the quarter ended Jun 30, 2026 was $37.02 million (quarter ended Mar 31, 2026), $17.87 million (quarter ended Dec 31, 2025) and $53.1 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | - |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 43.00 Mn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 6.00 Mn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 9.00 Mn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 47.70 Mn |
| 10 | Ascendis Pharma A | 14.12 Bn | 10.37 Bn | 362.22 Mn | 21.46 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.46 Mn |
| Mar 31, 2026 | 37.02 Mn |
| Dec 31, 2025 | 17.87 Mn |
| Sep 30, 2025 | 53.10 Mn |
| Jun 30, 2025 | 14.11 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 6.49 Mn |
| Jun 30, 2024 | 393,063.97 |
| Mar 31, 2024 | 23.04 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 6.74 Mn |
| Jun 30, 2023 | 226,496.27 |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 1.35 Mn |
| Jun 30, 2022 | 321,184.06 |
| Mar 31, 2022 | 432,100.02 |
| Dec 31, 2021 | 2.66 Mn |
| Sep 30, 2021 | 5.22 Mn |
Ascendis Pharma A Net Equity Issued and Repurchased API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-equity-issued-and-repurchased", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();